September 16, 2014—The fallout from last May’s 340B orphan drug exclusion court decision casts doubt over whether certain 340B program requirements are binding, a prominent attorney for manufacturers said at an industry conference in Chicago today.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)